Artículo
Pharmacokinetic Assessment of Novel Controlled Release Formulations of Ricobendazole Intended for Oral Administration in Dogs
Dib, Alicia; Paredes, Alejandro Javier
; Eliópulos, Natasha; Farias, Cristina Elena
; Suárez, Gonzalo; Aldrovandi, Ariel; Palma, Santiago Daniel
; Allemandi, Daniel Alberto
; Lanusse, Carlos Edmundo
; Sanchez Bruni, Sergio Fabian
![Icon](/themes/CONICETDigital/images/conicet.png)
![Icon](/themes/CONICETDigital/images/conicet.png)
![Icon](/themes/CONICETDigital/images/conicet.png)
![Icon](/themes/CONICETDigital/images/conicet.png)
![Icon](/themes/CONICETDigital/images/conicet.png)
![Icon](/themes/CONICETDigital/images/conicet.png)
Fecha de publicación:
12/2015
Editorial:
OMICS International
Revista:
Clinical & Experimental Pharmacology
ISSN:
2161-1459
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
The aim of this study was to evaluate the influence of different matrices developers on the pharmacokinetic behavior of Ricobendazole (RBZ) controlled release (CR) formulations and test their correlation in vitro-in vivo, using one Albendazole (ABZ)-based and one RBZ-based immediate-release formulation as references. The main excipients used for CR formulations were Hydroxypropyl Methyl Cellulose, Cetyl Alcohol, Gelucire 50/02® and Alginic Acid. Pharmacotechnical quality control tests were successfully completed. Twelve parasite-free no pregnant dogs were randomly divided into six groups and received different treatments (single oral doses) using an incomplete block design (two phases) (n=4). Phase I: treatment "A" (ABZ-based immediate-release formulation [25 mg/kg]). Treatment "B" (RBZ-based immediate release formulation [20 mg/kg]) and treatments from "C" to "F" (CR formulations [20 mg/kg]). Phase II was performed after 21 days of washout period. Blood samples were collected over 48 h and analysed by UV High Performance Liquid Chromatography. In vitro dissolution profiles showed that matrices agents favored a reservoir effect. Active metabolite Albendazole sulphoxide (ABZSO) or Ricobendazole (RBZ) plasma exposure measured in terms of area under concentration vs time curve (AUC) of all RBZ formulations was greater (p<0,05) when compared with that obtained for ABZ reference formulation. No statistical differences in AUC values were found among all RBZ formulations assayed (p>0.05). Nevertheless, RBZ-Cetyl alcohol formulation showed a statistical difference on its time peak concentration (p<0.05). In conclusion the results obtained in vitro do not correlate with those obtained in vivo, being this work useful to identify other matrices developers in RBZ-CR formulations.
Palabras clave:
Benzimidazoles
,
Canines
,
Anthelmintics
,
Matrices Developers
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(CIVETAN)
Articulos de CENTRO DE INVESTIGACION VETERINARIA DE TANDIL
Articulos de CENTRO DE INVESTIGACION VETERINARIA DE TANDIL
Articulos(UNITEFA)
Articulos de UNIDAD DE INVESTIGACION Y DESARROLLO EN TECNOLOGIA FARMACEUTICA
Articulos de UNIDAD DE INVESTIGACION Y DESARROLLO EN TECNOLOGIA FARMACEUTICA
Citación
Dib, Alicia ; Paredes, Alejandro Javier; Eliópulos, Natasha; Farias, Cristina Elena; Suárez, Gonzalo; et al.; Pharmacokinetic Assessment of Novel Controlled Release Formulations of Ricobendazole Intended for Oral Administration in Dogs; OMICS International; Clinical & Experimental Pharmacology; 5; 6; 12-2015; 1-8
Compartir
Altmétricas